The company announced that this campaign has covered all its financial requirements for the next two years, and that share ownership is divided between the founding partner, Llu\u00eds Ribas de Pouplana, and three other partners including Caixa Capital Semilla. <\/p>\n
Omnia Molecular is a spin-off of the PCB, the Institute for Research in Biomedicine, Barcelona (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA). It forms part of the PCB-Santander Bioincubator. <\/p>\n
The company’s activities centre on research into new antibiotic, antiparasitic and antifungal compounds. This work is based on technology developed by the company which allows it to accelerate the development of this type of pharmaceutical products. In addition to developing their own molecules, the company aims to adapt its technology and sell it to third parties. Llu\u00eds Ribas says that in the year 2010 Omnia expects to have a turnover of two million euros. <\/p>\n","protected":false},"excerpt":{"rendered":"
The biotechnology company Omnia Molecular<\/a>, located in the Barcelona Science Park (PCB), has announced the end of the first phase of its search for financial backing. The company has attracted 600,000 euros, which will be invested by the venture capital section of the la Caixa financial institution “Caixa Capital Semilla”<\/a>, and by the Centre for Industrial Technological Development (CDTI) through its Neotec project<\/a>. <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-45900","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"\n